MAPT and Alzheimer disease: Experimental data confirm these platforms can simultaneously quantify tau phosphorylation sites (p-tau181, p-tau217), Aβ42 oligomers, and glutamate concentration fluctuations, achieving 300 % higher throughput than single-analyte systems - a critical advancement for establishing multidimensional AD diagnostic models [73].